Combination therapy using exosome secretion inhibitor and immune checkpoint inhibitor
AssigneeResearch & Business Foundation Sungkyunkwan University
InventorsJae Hyung PARK, Jung Min SHIN, Soyoung SON, Sol SHIN, Seok Ho SONG, Chanho KIM, Torsha GHOSH, Kyung Hee HAN, Jeongyun KIM
Life of this patent
Estimating the term…
Abstract
A drug combination, an antibody-drug conjugate, and a polymer-drug conjugate are disclosed, for use in the combination therapy that uses as an exosome secretion inhibitor an endothelin receptor type A (ETA) antagonist, and an immune checkpoint inhibitor.
Claims22
A method of preventing or treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an endothelin receptor type A (ETA) antagonist and a therapeutically effective amount of an immune checkpoint inhibitor, wherein the ETA antagonist and the immune checkpoint inhibitor are administered simultaneously, separately, or sequentially.
A method of preventing or treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a conjugate of an endothelin receptor type A (ETA) antagonist conjugated to a biocompatible polymer and a therapeutically effective amount of an immune checkpoint inhibitor, wherein the conjugate and the immune checkpoint inhibitor are administered simultaneously, separately, or sequentially.
A method of preventing or treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a conjugate of an endothelin receptor type A (ETA) antagonist conjugated to an immune checkpoint inhibitor.
Dependencies are inferred from the claim text.